Ablynx Deploys IDBS to Speed Antibody Research and Discovery

E-WorkBook Provides R&D Data Management for Ablynx’s Product Pipeline

Guildford, UK, and Burlington, Mass., April 6, 2011 – IDBS, a global provider of innovative data management, analytics and modeling solutions, today announced that Ablynx has deployed E-WorkBook Suite to manage data associated with the discovery and development of Nanobodies®, a new class of antibody-derived therapeutic proteins for the treatment of major disease areas including inflammation, thrombosis, oncology and pulmonary disease.

E-WorkBook Suite is a robust and easy-to-use data management solution that is used across R&D sectors to maximize the value of R&D data, simplify workflows and protect Intellectual Property (IP) assets. It offers a compliant environment, enabling scientists to capture, analyze and share data in a single, secure environment. Ablynx chose E-WorkBook over a large number of LIMS and ELN systems based on its flexibility and rich functionality, specifically its ability to store data in context and search data with a versatile approach.

Dominique Vlieghe, Senior Bioinformatician at Ablynx commented: “In E-WorkBook we believe we have found a complete solution that will support both rigid and flexible workflows. E-WorkBook contains native functionality suited to our requirements.”

“We are delighted that E-WorkBook has been selected by Ablynx,” said Neil Kipling, founder and CEO of IDBS. “The solution will simplify the management of research data at Ablynx, enhancing productivity and efficiency throughout the organization. Working with Ablynx reflects IDBS’ continuing success with mid-size biotech companies and is testament to E-WorkBook’s position as the leading biologics solution.”

Ablynx will be presenting a case study at IDBS’ R&D Best Practice Seminar Series in June, more details are available online.

About Ablynx

Ablynx (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease. Today, the Company has over 25 projects in the pipeline and there are six Nanobodies in clinical development. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 270 people. More information can be found on www.ablynx.com.

About IDBS

IDBS is a global provider of innovative enterprise data management, analytics and modeling solutions. The company’s uniquely sophisticated platform technologies are used by more than 200 pharmaceutical companies, major healthcare providers, global leaders in academic study, and high tech companies to increase efficiency, reduce costs and improve the productivity of industrial R&D and clinical research. IDBS is clearly differentiated by its unique combination of award-winning enterprise technologies and domain knowledge in R&D.

IDBS’ solutions help scientists, hospitals and R&D businesses produce the world’s newest therapeutics, diagnostics and personalized treatments, faster, cleaner engines and fuels, breakthroughs in productive agriculture, healthy, safer food products, and high tech materials and consumer products.

Founded in 1989 and privately held, IDBS is headquartered in Guildford, UK with a direct sales and support presence worldwide. IDBS is a Profit Track 100 company and the recipient of multiple awards including the Frost and Sullivan ‘Enabling Technology’ Award in R&D data management for 2010 and Queen’s Award for International Trade 2011. Further information can be found at www.idbs.com, or follow us on Twitter @IDBSsoftware.